Palvella Therapeutics PVLA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.91M+157% | $2.59M+453% | $2.35M— | $1.91M— | $1.13M— | ||
| $28.1M+150% | $22.84M+180% | $18.26M— | $14.92M— | $11.24M— | ||
| $17.49M+95.0% | $15.76M+165% | $13.4M— | $11.63M— | $8.97M— | ||
| $45.59M+126% | $38.6M+174% | $31.66M— | $26.55M— | $20.21M— | ||
| $45.59M+126% | $38.6M+174% | $31.66M— | $26.55M— | $20.21M— | ||
| -$45.59M-126% | -$38.6M-174% | -$31.66M— | -$26.55M— | -$20.21M— | ||
| —— | —— | $818K— | $764K— | $267K— | ||
| -$49.3M-114% | -$41.72M-139% | -$32.95M— | -$28.38M— | -$23.08M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$49.3M-114% | -$41.72M-139% | -$32.95M-231% | -$28.38M-234% | -$23.08M-179% | ||
| -$4.17+41.7% | -$3.71+53.3% | -$2.63— | -$5.54— | -$7.15— | ||
| -$4.17+41.7% | -$3.71+53.3% | -$2.63— | -$5.54— | -$7.15— | ||
| 46.5M+177% | 44.4M+489% | 35.4M— | 26.1M— | 16.8M— | ||
| 46.5M+177% | 44.4M+489% | 35.4M— | 26.1M— | 16.8M— | ||
| —— | —— | —— | —— | -$1.48M— | ||
| -$6.64M-54.6% | -$5.82M-49.7% | -$5.2M— | -$4.71M— | -$4.3M— | ||
| —— | $0-100% | $494.5K— | $989K— | $1.48M— | ||
| -$49.2M-115% | -$41.64M-139% | -$32.27M— | -$28.11M— | -$22.89M— | ||
| $2.91M+157% | $2.59M+453% | $2.35M— | $1.91M— | $1.13M— | ||
| —— | —— | $104K— | -$111K— | -$3K— | ||
| —— | —— | $818K— | $764K— | $267K— | ||
| -$435K+33.1% | -$394K+37.8% | -$504K— | -$497K— | -$650K— | ||
| -$45.59M-126% | -$38.6M-174% | -$31.66M— | -$26.55M— | -$20.21M— | ||
| —— | —— | —— | —— | —— | ||
| -$45.59M-126% | -$38.6M-174% | -$31.66M— | -$26.55M— | -$20.21M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Palvella Therapeutics's income statement data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.